|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's Range||55.01 - 57.63|
|52 Week Range||46.47 - 64.82|
|Beta (5Y Monthly)||0.57|
|PE Ratio (TTM)||23.04|
|Forward Dividend & Yield||1.57 (2.77%)|
|Ex-Dividend Date||Mar 26, 2020|
|1y Target Est||69.45|
The biotechnology industry is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of diseases and medical conditions. Today's biotechnology industry includes companies that make medical devices and diagnostics, as well as biofuels, biomaterials, pollution controls, and more.
The Zacks Analyst Blog Highlights: Microsoft, salesforce.com, Novo Nordisk, American Express and Fiserv
Novo Nordisk A/S (CPH:NOVO B) stock is about to trade ex-dividend in 3 days time. You will need to purchase shares...
Top Analyst Reports for Microsoft, salesforce.com & Novo Nordisk
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
The Trump administration on Wednesday turned back to its pledge to fight high U.S. drug prices with a plan to limit the out-of-pocket cost for insulin, a life-saving medicine, to $35 per month for many people with diabetes who are enrolled in Medicare. The Center for Medicare and Medicaid Services, part of the U.S. Department of Health and Human Services, is lining up drug makers and the private insurers who manage Medicare drug benefits to volunteer to test out the new pricing in 2021. Medicare drug plans cover about 46 million people aged 65 and older and with disabilities.
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
Oscar Health is offering prescription drugs at rock-bottom prices, following the lead of other health care players responding to the public’s demand for lower costs.
FRANKFURT/LONDON, Feb 12 (Reuters) - Buyout fund Cinven has launched preparations for a potential stock market listing of German laboratory services group Synlab, while also sounding out potential buyers for a 5.5 billion euro ($6 billion) deal, sources close to the matter said. Cinven, which has backed Synlab since 2015, is working with investment banking boutique Lilja on the initial public offering (IPO), which could take place in the second half of the year, two sources said on condition of anonymity. Cinven and Lilja declined to comment.
It's been a good week for Novo Nordisk A/S (CPH:NOVO B) shareholders, because the company has just released its latest...
There are now 28,256 confirmed coronavirus cases in 25 countries and at least 565 deaths, according to the latest figures from the World Health Organization (WHO).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
Britain's brightest and best drug researchers are packing their bags as clinical trials start to dwindle, leaving a nation renowned as a global leader in pharmaceutical development to face a future in the slow lane. This is a worst-case scenario outlined by some scientists and industry experts in the wake of Brexit, which they say could deprive the country of its role as Europe's leader in early-stage drug research, designing and hosting pan-EU trials. Pamela Kearns, professor of paediatric oncology at the University of Birmingham, worries that over time Britain will in particular lose out in the field of medicines that treat rare diseases and childhood cancers, where trials often need to collaborate and recruit across Europe to find enough patients.
CVS Health Corp said on Wednesday its pharmacy benefit management (PBM) unit is launching a new program, under which employers and insurers will be able to offer diabetes drugs, including insulin, at no out-of-pocket costs to their members. The company said the program would not raise costs for health insurers and employers, and eliminating out-of-pocket costs would ensure better adherence by diabetic patients to their drug regimens. PBMs act as middlemen in the drug supply chain who negotiate prices for employers and health insurers.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune ...
Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.